TL;DR
This study reveals that quitting smoking after a cancer diagnosis is linked to a higher risk of elevated neutrophil-to-lymphocyte ratio (NLR) in tobacco use-related (TUR) cancer survivors, particularly among Non-Hispanic Black (NHB) individuals. The findings suggest that the timing of smoking cessation is crucial, with NHB survivors who quit after diagnosis facing the highest risk, underscoring the importance of immediate cessation for this group.
What Problem Does This Paper Address?
Smoking is a major risk factor for many cancers, and quitting after a diagnosis is widely recommended to improve outcomes. However, the precise impact of when someone quits smoking relative to their cancer diagnosis on specific health markers remains an area needing further exploration. The neutrophil-to-lymphocyte ratio (NLR) is an emerging biomarker associated with inflammation and prognosis in various diseases, including cancer. Previous research has indicated that continued smoking can lead to higher NLR levels. This paper aims to dissect the relationship between different smoking cessation timelines (before diagnosis, after diagnosis, or continued smoking) and the risk of having a high NLR among survivors of tobacco use-related cancers, with a specific focus on understanding potential racial disparities in these associations.
Methods
The researchers utilized a large, nationally representative dataset from the National Health and Nutritional Examination Survey (NHANES) from 1999-2018. They analyzed data from 1263 adult cancer survivors diagnosed with tobacco use-related cancers. The primary outcome of interest was the neutrophil-to-lymphocyte ratio (NLR), categorized into "high-risk" (≥ 3) and "low-risk" (< 3).
Key methodological aspects include:
- Weighted Logistic Regression: This statistical technique was employed to account for the complex survey design of NHANES and to analyze the association between smoking cessation time and the risk of a high NLR.
- Stratified Analysis: The study performed detailed analyses, including stratifying by race (Non-Hispanic White vs. Non-Hispanic Black) to investigate potential racial disparities in the observed associations.
- Covariate Adjustment: The models were adjusted for several potential confounding factors, such as age, gender, chronic disease status, cancer type, body mass index (BMI), education level, and years after cancer diagnosis (YACD), to isolate the effects of smoking cessation timing.
- Smoking Status Categorization: Participants were categorized into distinct smoking groups: nonsmokers, former smokers who quit 5+ years before diagnosis (FS1), former smokers who quit < 5 years before diagnosis (FS2), former smokers who quit after diagnosis (FS3), and current smokers (CS).
Datasets
The study exclusively used data from the National Health and Nutritional Examination Survey (NHANES) 1999-2018. This is a publicly available, cross-sectional dataset that collects health and nutritional information from a representative sample of the U.S. population. No new datasets were introduced.
Key Insights and Ideas
- Timing is Everything (Especially for NHB Survivors): The most striking finding is that for Non-Hispanic Black (NHB) cancer survivors, quitting smoking after a cancer diagnosis is associated with the highest risk of a high NLR. This suggests that while quitting is generally beneficial, the immediate post-diagnosis period might be a critical window where cessation timing has a particularly pronounced impact on this inflammatory marker for this demographic.
- Racial Disparities in NLR Risk: The study highlights significant differences in NLR risk between Non-Hispanic White (NHW) and NHB individuals. While NHW survivors had higher NLR associated with older age and respiratory cancers, NHB survivors who quit smoking after diagnosis, or even less than 5 years before diagnosis, showed a markedly increased risk of high NLR.
- NLR as a Potential Indicator of Inflammation Post-Cessation: The elevated NLR observed in certain smoking cessation groups, particularly NHB individuals quitting after diagnosis, suggests that this inflammatory marker might reflect complex physiological responses to both cancer and smoking cessation.
- Broader Implications for Smoking Cessation Strategies: The findings underscore the need for tailored smoking cessation interventions that consider not only the act of quitting but also the timing and the specific demographic characteristics of cancer survivors.
Key Results
- Prevalence of High NLR: Approximately 28.2% of the studied cancer survivors had high-risk NLR levels (≥ 3).
- NHB Survivors Quitting After Diagnosis: NHB individuals who quit smoking after a cancer diagnosis (FS3) showed the highest odds of a high NLR (OR 4.83, 95% CI 1.40–16.61, p = 0.01) compared to NHB nonsmokers.
- Other NHB Associations: NHB individuals who quit smoking less than 5 years before a cancer diagnosis (FS2) and current smokers (CS) also had higher odds of high-risk NLR compared to NHB nonsmokers.
- NHW Associations: For NHW survivors, older age (≥ 75 years), male gender, and respiratory-related cancers were associated with a higher risk of high NLR.
- Gender Impact: Female cancer survivors, in general, had lower odds of high-risk NLR compared to males (OR 0.63, CI 0.42-0.94, p = 0.02).
- Cancer Type Impact: Non-respiratory cancers were associated with lower odds of high-risk NLR compared to respiratory cancers.
- Age Impact: Individuals aged 75 years and older had higher odds of high-risk NLR compared to those younger than 45.
- Smoking Cessation Time: While unadjusted analyses showed associations between different smoking cessation times and high NLR, these associations largely disappeared after adjusting for covariates, suggesting that race plays a significant role in mediating these relationships.
Limitations and Future Work
- Self-Reported Data: The study relies on self-reported data for smoking status, cancer diagnosis, and other health information, which can introduce recall bias.
- Cross-Sectional Design: The study's cross-sectional nature prevents the establishment of causal relationships between smoking cessation timing and NLR levels.
- Data Combination: Combining multiple 2-year survey cycles might lead to overcounting participants with certain cancer types.
- Chemotherapy Effects: The study could not exclude participants who received chemotherapy, which can influence NLR levels.
- Exclusion of Certain Cancers: The exclusion of individuals with very low survival rates (e.g., pancreatic cancer) might introduce bias.
- Generalizability to Hospitalized Patients: The findings might not be directly applicable to hospitalized cancer patients.
Future Work: The authors suggest further research to:
- Investigate potential barriers preventing older NHW individuals (≥ 75 years) from quitting smoking after a cancer diagnosis.
- Develop targeted smoking cessation interventions for current NHB smokers undergoing cancer screening.
- Conduct survival analyses to explore the relationship between NLR and mortality in this population.
- Explore the mental health-related data for TUR cancer survivors to understand the role of emotions in smoking cessation.
Summary updated